India’s largest pharmaceutical company, Sun Pharmaceutical Industries has reported robust financial results for the financial year ended March 31, 2026, while also announcing a final dividend of ₹5 per equity share for shareholders.
According to the company’s filing with stock exchanges, Sun Pharma recorded consolidated revenue from operations of ₹5.92 lakh crore during FY26, compared to ₹5.63 lakh crore in the previous financial year, reflecting steady business growth across global markets. The company also posted strong profitability despite higher research and development investments and exceptional charges during the year.
The Board of Directors approved the audited standalone and consolidated financial results during its meeting held on May 22, 2026. Alongside the earnings announcement, the company recommended a final dividend of ₹5 per share in addition to the interim dividend of ₹11 per share already declared earlier this year.
Sun Pharma’s standalone net profit for FY26 stood at ₹26,234.2 million, while total comprehensive income reached ₹24,043.7 million. Research and development expenditure increased significantly to ₹21,635 million, underlining the company’s continued focus on innovation and specialty therapies.
The company also disclosed exceptional items amounting to ₹5,463.4 million during the year. These included impairment and discontinuation-related costs associated with the development of SCD-044, along with expenses linked to implementation of India’s new labour codes.
In another key development, Sun Pharma confirmed that the National Company Law Tribunal (NCLT) approved the merger of five wholly-owned subsidiaries into the parent company. The merger is expected to streamline operations and improve organizational efficiency.
